{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T07:52:49Z","timestamp":1766908369915,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12288-021-01434-9","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T15:09:43Z","timestamp":1617289783000},"page":"51-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Superior Cytotoxicity of Dual Targeting of BCR\/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML"],"prefix":"10.1007","volume":"38","author":[{"given":"Reza","family":"Shiri Heris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atieh","family":"Pourbagheri-Sigaroodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir-Mohammad","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-4920","authenticated-orcid":false,"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"issue":"3","key":"1434_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93(3):442\u2013459","journal-title":"Am J Hematol"},{"issue":"7","key":"1434_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstr\u00f6m K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M et al (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood J Am SocHematol 122(7):1284\u20131292","journal-title":"Blood J Am SocHematol"},{"issue":"11","key":"1434_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.clml.2018.06.029","volume":"18","author":"P Chopade","year":"2018","unstructured":"Chopade P, Akard LP (2018) Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 18(11):710\u2013723","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"50","key":"1434_CR4","doi-asserted-by":"publisher","first-page":"39223","DOI":"10.1074\/jbc.M007291200","volume":"275","author":"F Gesbert","year":"2000","unstructured":"Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD (2000) BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase\/AKT pathway. J Biol Chem 275(50):39223\u201339230","journal-title":"J Biol Chem"},{"issue":"5","key":"1434_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/cgt.2014.65","volume":"22","author":"Q Li","year":"2015","unstructured":"Li Q, Wu Y, Fang S, Wang L, Qi H, Zhang Y et al (2015) BCR\/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts. Cancer Gene Ther 22(5):227\u2013237","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"1434_CR6","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cbin.11322","volume":"44","author":"R Shiri Heris","year":"2020","unstructured":"Shiri Heris R, Safaroghli-Azar A, Yousefi AM, Hamidpour M, Bashash D (2020) Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity. Cell Biol Int 44(5):1212\u20131223","journal-title":"Cell Biol Int"},{"issue":"10","key":"1434_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/ml200156t","volume":"2","author":"MT Burger","year":"2011","unstructured":"Burger MT, Pecchi S, Wagman A, Ni Z-J, Knapp M, Hendrickson T et al (2011) Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett 2(10):774\u2013779","journal-title":"ACS Med Chem Lett"},{"key":"1434_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biocel.2017.08.009","volume":"91","author":"D Bashash","year":"2017","unstructured":"Bashash D, Delshad M, Safaroghli-Azar A, Safa M, Momeny M, Ghaffari SH (2017) Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: an emerging mechanism of action of BKM120. Int J Biochem Cell Biol 91:1\u20138","journal-title":"Int J Biochem Cell Biol"},{"key":"1434_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.biocel.2016.09.004","volume":"79","author":"D Bashash","year":"2016","unstructured":"Bashash D, Safaroghli-Azar A, Delshad M, Bayati S, Nooshinfar E, Ghaffari SH (2016) Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: shedding new light on NVP-BKM120 mechanism of action. Int J Biochem Cell Biol 79:308\u2013317","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"1434_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ijc.27989","volume":"133","author":"L Amrein","year":"2013","unstructured":"Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L (2013) The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int J Cancer 133(1):247\u2013252","journal-title":"Int J Cancer"},{"key":"1434_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejphar.2018.10.036","volume":"842","author":"A Safaroghli-Azar","year":"2019","unstructured":"Safaroghli-Azar A, Bashash D, Kazemi A, Pourbagheri-Sigaroodi A, Momeny M (2019) Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: shedding new light on the mechanisms involved in BKM120 resistance. Eur J Pharmacol 842:89\u201398","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1434_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3109\/10428194.2013.806800","volume":"55","author":"C Zang","year":"2014","unstructured":"Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K et al (2014) Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk Lymphoma 55(2):425\u2013434","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1434_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/13543784.2017.1384814","volume":"26","author":"P Robak","year":"2017","unstructured":"Robak P, Robak T (2017) Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26(11):1249\u20131265","journal-title":"Expert Opin Investig Drugs"},{"key":"1434_CR14","doi-asserted-by":"publisher","first-page":"105615","DOI":"10.1016\/j.biocel.2019.105615","volume":"116","author":"F Alipour","year":"2019","unstructured":"Alipour F, Riyahi N, Safaroghli-Azar A, Sari S, Zandi Z, Bashash D (2019) Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO). Int J Biochem Cell Biol 116:105615","journal-title":"Int J Biochem Cell Biol"},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejphar.2018.10.007","volume":"841","author":"D Bashash","year":"2018","unstructured":"Bashash D, Delshad M, Riyahi N, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Momeny M (2018) Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: proposing novel therapeutic potential for BKM120. Eur J Pharmacol 841:10\u201318","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1434_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/ijo.2011.1290","volume":"40","author":"E Park","year":"2012","unstructured":"Park E, Park J, Han S-W, Im S-A, Kim T-Y, Oh D-Y et al (2012) NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol 40(4):1259\u20131266","journal-title":"Int J Oncol"},{"key":"1434_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.biocel.2018.08.010","volume":"103","author":"D Bashash","year":"2018","unstructured":"Bashash D, Safaroghli-Azar A, Bayati S, Razani E, Pourbagheri-Sigaroodi A, Gharehbaghian A et al (2018) Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-\u03baB axis: shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol 103:105\u2013114","journal-title":"Int J Biochem Cell Biol"},{"key":"1434_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ejphar.2016.09.006","volume":"791","author":"S Bayati","year":"2016","unstructured":"Bayati S, Bashash D, Ahmadian S, Safaroghli-Azar A, Alimoghaddam K, Ghavamzadeh A et al (2016) Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt\/p53 axis in pre-B acute lymphoblastic leukemia cells. Eur J Pharmacol 791:274\u2013283","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1434_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2141.1995.tb05358.x","volume":"91","author":"A Serra","year":"1995","unstructured":"Serra A, Gottardi E, Ragione FD, Saglio G, Iolascon A (1995) Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol 91(3):625\u2013629","journal-title":"Br J Haematol"},{"issue":"1","key":"1434_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11899-012-0152-z","volume":"8","author":"KM Polakova","year":"2013","unstructured":"Polakova KM, Koblihova J, Stopka T (2013) Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep 8(1):28\u201336","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"1434_CR21","doi-asserted-by":"publisher","first-page":"e88298","DOI":"10.1371\/journal.pone.0088298","volume":"9","author":"F-F Huang","year":"2014","unstructured":"Huang F-F, Zhang L, Wu D-S, Yuan X-Y, Chen F-P, Zeng H et al (2014) PTEN regulates BCRP\/ABCG2 and the side population through the PI3K\/Akt pathway in chronic myeloid leukemia. PLoS ONE 9(3):e88298","journal-title":"PLoS ONE"},{"issue":"3","key":"1434_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, De Jonge M, Verweij J, Birle D et al (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J ClinOncol Off J Am SocClinOncol 30(3):282\u2013290","journal-title":"J ClinOncol Off J Am SocClinOncol"},{"issue":"7","key":"1434_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/07357907.2019.1651328","volume":"37","author":"N Riyahi","year":"2019","unstructured":"Riyahi N, Safaroghli-Azar A, Sheikh-Zeineddini N, Sayyadi M, Bashash D (2019) Synergistic effects of PI3K and c-Myc co-targeting in acute leukemia: shedding new light on resistance to selective PI3K-\u03b4 inhibitor CAL-101. Cancer Invest 37(7):311\u2013324","journal-title":"Cancer Invest"},{"key":"1434_CR24","doi-asserted-by":"crossref","unstructured":"Sayyadi M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Abolghasemi H, Anoushirvani AA, Bashash D. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K\/NF-\u03baB Axis. Archives of medical research. 2020.","DOI":"10.1016\/j.arcmed.2020.06.002"},{"issue":"4","key":"1434_CR25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/PPO.0000000000000135","volume":"21","author":"A Afghahi","year":"2015","unstructured":"Afghahi A, Sledge GW Jr (2015) Targeted therapy for cancer in the genomic era. Cancer J 21(4):294\u2013298","journal-title":"Cancer J"},{"issue":"1","key":"1434_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1079-9796(03)00070-6","volume":"31","author":"K Kawauchi","year":"2003","unstructured":"Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S-I (2003) Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 31(1):11\u20137","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"1434_CR27","first-page":"4652","volume":"9","author":"X-Y Wang","year":"2017","unstructured":"Wang X-Y, Zhang X-H, Peng L, Liu Z, Yang Y-X, He Z-X et al (2017) Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K\/Akt\/mTOR and p38 MAPK\/Erk1\/2 signaling pathways in K562 cells. Am J Transl Res 9(10):4652","journal-title":"Am J Transl Res"},{"key":"1434_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.biocel.2017.02.007","volume":"85","author":"D Bashash","year":"2017","unstructured":"Bashash D, Safaroghli-Azar A, Dadashi M, Safa M, Momeny M, Ghaffari SH (2017) Anti-tumor activity of PI3K-\u03b4 inhibitor in hematologic malignant cells: shedding new light on resistance to Idelalisib. Int J Biochem Cell Biol 85:149\u2013158","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"1434_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/CAD.0000000000000477","volume":"28","author":"A Safaroghli-Azar","year":"2017","unstructured":"Safaroghli-Azar A, Bashash D, Sadreazami P, Momeny M, Ghaffari SH (2017) PI3K-\u03b4 inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. Anticancer Drugs 28(4):436\u2013445","journal-title":"Anticancer Drugs"},{"issue":"6","key":"1434_CR30","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00280-012-1869-z","volume":"69","author":"A Mueller","year":"2012","unstructured":"Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR et al (2012) Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 69(6):1601\u20131615","journal-title":"Cancer Chemother Pharmacol"},{"key":"1434_CR31","doi-asserted-by":"crossref","unstructured":"Sattlermc M, Griffin JD, editors. Molecular mechanisms of transformation by the BCR-ABL oncogene. Seminars in hematology; 2003: Elsevier.","DOI":"10.1053\/shem.2003.50034"},{"issue":"5","key":"1434_CR32","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2010","unstructured":"Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L et al (2010) Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95(5):819\u201328","journal-title":"Haematologica"},{"issue":"3","key":"1434_CR33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y et al (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood J Am SocHematol 114(3):647\u2013650","journal-title":"Blood J Am SocHematol"},{"issue":"25","key":"1434_CR34","doi-asserted-by":"publisher","first-page":"22291","DOI":"10.1074\/jbc.M111.236596","volume":"286","author":"X Li","year":"2011","unstructured":"Li X, Wen W, Liu K, Zhu F, Malakhova M, Peng C et al (2011) Phosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell lines. J Biol Chem 286(25):22291\u201322299","journal-title":"J Biol Chem"},{"issue":"5","key":"1434_CR35","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3892\/ijo_00000777","volume":"37","author":"Z Wang","year":"2010","unstructured":"Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C et al (2010) Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level. Int J Oncol 37(5):1315\u20131321","journal-title":"Int J Oncol"},{"issue":"3","key":"1434_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1677\/jme.1.02118","volume":"37","author":"N Cosgrave","year":"2006","unstructured":"Cosgrave N, Hill AD, Young LS (2006) Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol 37(3):377\u2013390","journal-title":"J Mol Endocrinol"},{"issue":"15","key":"1434_CR37","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1074\/jbc.RA118.005621","volume":"294","author":"G Jiang","year":"2019","unstructured":"Jiang G, Huang C, Liao X, Li J, Wu X-R, Zeng F et al (2019) The RING domain in the anti-apoptotic protein XIAP stabilizes c-Myc protein and preserves anchorage-independent growth of bladder cancer cells. J Biol Chem 294(15):5935\u20135944","journal-title":"J Biol Chem"},{"key":"1434_CR38","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.biopha.2018.03.009","volume":"102","author":"B Toosi","year":"2018","unstructured":"Toosi B, Zaker F, Alikarami F, Kazemi A, Ardestanii MT (2018) VS-5584 as a PI3K\/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-\u03baB activity in B cell precursor-acute lymphoblastic leukemia. Biomed Pharmacother 102:428\u2013437","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"1434_CR39","doi-asserted-by":"publisher","first-page":"14004","DOI":"10.1002\/jcb.28675","volume":"120","author":"N Sheikh-Zeineddini","year":"2019","unstructured":"Sheikh-Zeineddini N, Bashash D, Safaroghli-Azar A, Riyahi N, Shabestari RM, Janzamin E et al (2019) Suppression of c-Myc using 10058\u2013F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells. J Cell Biochem 120(8):14004\u201314016","journal-title":"J Cell Biochem"},{"key":"1434_CR40","doi-asserted-by":"publisher","first-page":"172821","DOI":"10.1016\/j.ejphar.2019.172821","volume":"870","author":"N Sheikh-Zeineddini","year":"2020","unstructured":"Sheikh-Zeineddini N, Safaroghli-Azar A, Salari S, Bashash D (2020) C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: proposing a probable mechanism of action for 10058\u2013F4. Eur J Pharmacol 870:172821","journal-title":"Eur J Pharmacol"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01434-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-021-01434-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-021-01434-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T09:31:50Z","timestamp":1643621510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-021-01434-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1007\/s12288-021-01434-9","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"type":"print","value":"0971-4502"},{"type":"electronic","value":"0974-0449"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"22 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}